Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Stoy

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Science Translational Medicine|October 18, 2013
Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heartRonald J Vagnozzi, Gregory J Gatto, Lara S Kallander, et al.
Journal of Medicinal Chemistry|October 19, 2018
Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4)Edward J Brnardic, Guosen Ye, Carl Brooks, et al.
JCO Oncology Practice|December 20, 2024
Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing AdministrationTyler B Sandahl, Scott A Soefje, Rafael Fonseca, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4)Carl A Brooks, Linda S Barton, David J Behm, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2009
Improving the developability profile of pyrrolidine progesterone receptor partial agonistsLara S Kallander, David G Washburn, Tram H Hoang, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Science Translational Medicine|October 18, 2013
Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heartRonald J Vagnozzi, Gregory J Gatto, Lara S Kallander, et al.
Journal of Medicinal Chemistry|October 19, 2018
Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4)Edward J Brnardic, Guosen Ye, Carl Brooks, et al.
JCO Oncology Practice|December 20, 2024
Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing AdministrationTyler B Sandahl, Scott A Soefje, Rafael Fonseca, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4)Carl A Brooks, Linda S Barton, David J Behm, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2009
Improving the developability profile of pyrrolidine progesterone receptor partial agonistsLara S Kallander, David G Washburn, Tram H Hoang, et al.
Pageof 2